COVID-Anosmia Checker: A rapid and low-cost alternative tool for mass screening of COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
COVID-19 curve can be flattened by adopting mass screening protocols with aggressive testing and isolating infected populations. The current approach largely depends on RT-PCR/rapid antigen tests that require expert personnel resulting in higher costs and reduced testing frequency. Loss of smell is reported as a major symptom of COVID-19, however, a precise olfactory testing tool to identify COVID-19 patient is still lacking.
Methods
To quantitatively check for the loss of smell, we developed an odor strip, “ COVID-Anosmia checker” , spotted with gradients of coffee and lemon grass oil. We validated its efficiency in healthy and COVID-19 positive subjects. A trial screening to identify SARS-CoV-2 infected persons was also carried out to check the sensitivity and specificity of our screening tool.
Findings
It was observed that COVID positive participants were hyposmic instead of being anosmic when they were subjected to smelling higher odor concentration. Our tool identified 97% of symptomatic and 94% of asymptomatic COVID-19 positive subjects after excluding most confounding factors like concurrent chronic sinusitis. Further, it was possible to reliably predict COVID-19 infection by calculating a loss of smell score with 100% specificity. We coupled this tool with a mobile application, which takes the input response from the user, and can readily categorize the user in the appropriate risk groups.
Conclusion
Loss of smell can be used as a reliable marker for screening for COVID-19. Our tool can be used for first-line screening to trace out COVID-19 infection effectively. It can be used in difficult to reach geographical locations.
Article activity feed
-
SciScore for 10.1101/2020.10.28.20221200: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Inclusion criteria were: Age 20-60 years, with an oral consent to participate.
IRB: The study was approved by the Institutional Human Ethics Committee of Rajiv Gandhi Center for Biotechnology (RGCB/IHEC/250/2020/28) and Saveetha Medical College Hospital (002/08/2020/IEC/SMCH).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Both males and females were included in the study. Table 2: Resources
Software and Algorithms Sentences Resources Statistical Analysis: Data were analyzed using IBM SPSS 20.0, Microsoft Excel, and visualized using R Studio ggplot2 package. SPSSsuggested: (SPSS, RRID:SCR_002865)Microsoft …SciScore for 10.1101/2020.10.28.20221200: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Inclusion criteria were: Age 20-60 years, with an oral consent to participate.
IRB: The study was approved by the Institutional Human Ethics Committee of Rajiv Gandhi Center for Biotechnology (RGCB/IHEC/250/2020/28) and Saveetha Medical College Hospital (002/08/2020/IEC/SMCH).Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Both males and females were included in the study. Table 2: Resources
Software and Algorithms Sentences Resources Statistical Analysis: Data were analyzed using IBM SPSS 20.0, Microsoft Excel, and visualized using R Studio ggplot2 package. SPSSsuggested: (SPSS, RRID:SCR_002865)Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)R Studiosuggested: Noneggplot2suggested: (ggplot2, RRID:SCR_014601)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-